Gilead Acquires Phase I Oral Cyclic Peptide IL-23R Inhibitor in 1.275 Billion Dollar Upfront Deal

On October 22, Gilead announced an upfront acquisition of a Phase I oral cyclic peptide IL-23R inhibitor for 1.275 billion US dollars, with no milestone payments or sales royalties. The 1.275 billion dollars is about 8.5 billion RMB, which the author says sets a record for a Chinese molecule deal, equivalent to paying out a 1.5 billion dollar total package for a single Phase I molecule all at once.